POLYMER-ENCAPSULATED GENETICALLY-MODIFIED CELLS CONTINUE TO SECRETE HUMAN NERVE GROWTH-FACTOR FOR OVER ONE-YEAR IN RAT VENTRICLES - BEHAVIORAL AND ANATOMICAL CONSEQUENCES

Citation
Sr. Winn et al., POLYMER-ENCAPSULATED GENETICALLY-MODIFIED CELLS CONTINUE TO SECRETE HUMAN NERVE GROWTH-FACTOR FOR OVER ONE-YEAR IN RAT VENTRICLES - BEHAVIORAL AND ANATOMICAL CONSEQUENCES, Experimental neurology, 140(2), 1996, pp. 126-138
Citations number
45
Categorie Soggetti
Neurosciences
Journal title
ISSN journal
00144886
Volume
140
Issue
2
Year of publication
1996
Pages
126 - 138
Database
ISI
SICI code
0014-4886(1996)140:2<126:PGCCTS>2.0.ZU;2-W
Abstract
The long-term delivery of growth factors and other proteins into the C NS at putatively therapeutic yet safe levels continues to be technical ly constrained. fn the present studies, the gene encoding human nerve growth factor (hNGF), introduced into a dihydrofolate reductase-based pNUT expression vector system, was engineered into a clonal. baby hams ter kidney (BHK) cell line. BHK-hNGF23 and mock-transfected cells were encapsulated in an immunoisolating polymeric device and transplanted into the lateral ventricles of healthy young adult rats for 13.5 month s. As measured by ELISA, nanogram quantities of hNGF were released by encapsulated cells both prior to implantation (3.6 +/- 0.8 ng/device/2 4 h) and upon removal from rat lateral ventricles after 13.5 months in vivo (2.2 +/- 0.4 ng/device/24 h). In addition, the hNGF released int o the tissue culture medium was biologically active. Longterm encapsul ated cell survival was confirmed by histologic analysis. The presence of genomic DNAs (hNGF transgene), as determined by PCR analyses, revea led that the transgene copy number from the recovered BHK-hNGF23 cells after 13.5 months in vivo was equivalent to preimplant levels. No del eterious effects from hNGF were detectable on body weight, mortality r ate, motor/ambulatory function, or cognitive function as assessed with the Morris water maze and delayed matching to position in healthy you ng adult rats. in addition, there was no evidence that hNGF from these encapsulated cells produced hyperalgesia. Only tests of somatosensory thresholds revealed statistically significant effects related to the hNGF delivered in the present study, and that effect was Limited to a decrease in the number of trials to asymptote. Animals receiving BHK-h NGF23 implants exhibited a marked hypertrophy of cholinergic neurons w ithin the striatum (22% increase) and nucleus basalis (7% increase) bu t not the medial septum ipsilateral to the capsule. Moreover a robust sprouting of cholinergic fibers was observed within the frontal cortex and lateral septum proximal to the implant. These results indicate th at encapsulated xenogeneic cells provide a safe and effective method f or the long-term delivery of hNGF and potentially other neurotrophic f actors within the CNS. (C) 1996 Academic Press, Inc.